(0.31%) 5 115.73 points
(0.32%) 38 361 points
(0.33%) 15 981 points
(-0.94%) $83.06
(5.51%) $2.03
(0.36%) $2 355.60
(0.42%) $27.65
(4.01%) $959.10
(-0.24%) $0.932
(-0.41%) $10.98
(-0.55%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe...
Stats | |
---|---|
本日の出来高 | 4 497.00 |
平均出来高 | 98 766.00 |
時価総額 | 13.91M |
EPS | $0 ( 2024-03-28 ) |
次の収益日 | ( $-0.600 ) 2024-07-04 |
Last Dividend | $0.220 ( 2015-06-05 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.370 |
ATR14 | $0.0290 (1.59%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2004-02-13 | Robert R Mccormick Tribune Foundation | Sell | 65 200 | Common Stock |
2004-02-17 | Robert R Mccormick Tribune Foundation | Sell | 92 000 | Common Stock |
2004-02-18 | Robert R Mccormick Tribune Foundation | Sell | 17 800 | Common Stock |
INSIDER POWER |
---|
0.00 |
Last 3 transactions |
Buy: 0 | Sell: 175 000 |
Trinity Biotech PLC 相関
10 最も負の相関 | |
---|---|
SVAC | -0.899 |
AUPH | -0.891 |
USCR | -0.88 |
RARE | -0.879 |
PAIC | -0.877 |
MLVF | -0.866 |
EZGO | -0.865 |
SUMR | -0.863 |
AMYT | -0.861 |
IIN | -0.859 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Trinity Biotech PLC 財務諸表
Annual | 2023 |
収益: | $56.83M |
総利益: | $18.50M (32.56 %) |
EPS: | $-15.69 |
FY | 2023 |
収益: | $56.83M |
総利益: | $18.50M (32.56 %) |
EPS: | $-15.69 |
FY | 2022 |
収益: | $74.78M |
総利益: | $22.05M (29.48 %) |
EPS: | $-6.08 |
FY | 2021 |
収益: | $92.97M |
総利益: | $38.08M (40.96 %) |
EPS: | $0.0400 |
Financial Reports:
No articles found.
Trinity Biotech PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.400 | 2011-06-07 |
Last Dividend | $0.220 | 2015-06-05 |
Next Dividend | $0 | N/A |
Payout Date | 2015-07-01 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | $1.190 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.55 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2011 | $0.400 | 4.67% |
2012 | $0.150 | 1.49% |
2013 | $0.200 | 1.36% |
2014 | $0.220 | 0.88% |
2015 | $0.220 | 1.21% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.431 | 1.500 | -8.63 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.412 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | 1.650 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.60 | 0.800 | 2.02 | 1.613 | [1 - 3] |
quickRatioTTM | 1.271 | 0.800 | 7.23 | 5.78 | [0.8 - 2.5] |
cashRatioTTM | 0.245 | 1.500 | 9.75 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.923 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -2.41 | 1.000 | -2.00 | -2.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -8.33 | 2.00 | -2.78 | -5.55 | [0 - 30] |
freeCashFlowPerShareTTM | -10.09 | 2.00 | -5.05 | -10.00 | [0 - 20] |
debtEquityRatioTTM | -2.29 | -1.500 | -9.16 | 10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.334 | 1.000 | 7.76 | 7.76 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.471 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.233 | 1.000 | -2.40 | -2.40 | [0.2 - 2] |
assetTurnoverTTM | 0.956 | 0.800 | 6.96 | 5.57 | [0.5 - 2] |
Total Score | -1.023 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.114 | 1.000 | -0.113 | 0 | [1 - 100] |
returnOnEquityTTM | 1.650 | 2.50 | 10.00 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -10.09 | 2.00 | -3.36 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -8.33 | 2.00 | -2.78 | -5.55 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00148 | 1.500 | -3.32 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.225 | 1.000 | -8.12 | 0 | [0.1 - 0.5] |
Total Score | -1.549 |
Trinity Biotech PLC
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。